


PHARMACEUTICAL 2022



Harmony Biosciences Holdings Inc. Rank 65 of 475







PHARMACEUTICAL 2022





Harmony Biosciences Holdings Inc. Rank 65 of 475

The relative strengths and weaknesses of Harmony Biosciences Holdings Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Harmony Biosciences Holdings Inc. compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 391% points. The greatest weakness of Harmony Biosciences Holdings Inc. is the variable Liabilities, Non-Current, reducing the Economic Capital Ratio by 81% points.

The company's Economic Capital Ratio, given in the ranking table, is 102%, being 378% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	284,439
Cost of Goods Sold	55,518
Intangible Assets	143,919
Liabilities, Current	53,775
Liabilities, Non-Current	193,161
Other Assets	4,265
Other Compr. Net Income	0
Other Expenses	70,949
Other Liabilities	0
Other Net Income	-50,100
Property and Equipment	820
Research and Development	30,367
Revenues	305,440
Selling, General and Administrative Expense	63,909

Output Variable	Value in 1000 USD
Assets	433,443
Liabilities	246,936
Expenses	220,743
Stockholders Equity	186,507
Net Income	34,597
Comprehensive Net Income	34,597
Economic Capital Ratio	102%

